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DESCRIPTION OF THE EVIDENCE COLLECTION METHOD
Articles found in MEDLINE databases (PubMed) and other 
research sources, with no time limit, were reviewed. The search 
strategy used was based on structured questions in the PICO 
format (Patient, Intervention, Comparison, and Outcome). 
The following descriptors were used: crack cocaine, cocaine, 
cocaine-related disorders, substance-related disorders, 
behavior, addictive; incidence, prevalence, risk, signs 
and symptoms, chronic disease, acute disease, cocaine/
poisoning, cocaine/toxicity, emergency service, hospital; 
nervous system diseases/chemically induced, psychoses, 
substance-induced; abnormalities, drug-induced; adverse 
effects, complications, substance withdrawal syndrome; 
rehabilitation, ambulatory care, comorbidity, mental 
disorders, diagnosis, urine, analysis, hair/chemistry, crack 
cocaine/pharmacology, cocaine/analysis, substance abuse 
detection, forensic toxicology, brain, brain mapping, 
brain/radionuclide imaging, tomography, emission-
computed; positron-emission tomography, fetus, infant, 
newborn; infant premature, neonatal screening, infant, 
child, preschool; child, adolescent, prenatal exposure 
delayed effects, neonatal abstinence syndrome, child 
development/drug effects, child behavior/drug effects, 
intelligence, growth, developmental disabilities/chemically 
induced, language development, neuropsychological 
tests, cognition, psychomotor performance, pregnancy, 
pregnancy complications, pregnancy outcome, genetics. 
These descriptors were used to cross-check each topic of 
PICO questions according to the theme. After examining 
the retrieved material, the articles concerning the questions 
that provided the evidence supporting this guideline were 
selected.
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DEGREE OF RECOMMENDATION AND STRENGTH OF EVIDENCE
A: Experimental or observational studies of higher 
consistency.
B: Experimental or observational studies of lower 
consistency.
C: Case reports (non-controlled studies).
D: Opinions without critical evaluation, based on 
consensus, physiological studies, or animal models.
INTRODUCTION
Cocaine reemerged in Brazil in the last twenty years1 (B). 
Since then, new patterns of drug consumption and pre-
sentations have been introduced2 (B). Currently, cocaine 
consumption affects all social strata3 (B). Cocaine and 
crack are consumed by 0.3% of the world’s population4(D). 
Most users are concentrated in the Americas (70%), and 
the number of users has increased in the last decade5 (D). 
Among the emerging countries, Brazil is the largest mar-
ket in South America in absolute numbers, with more than 
900,000 cocaine users —nearly triple the number of previ-
ous surveys6 (D). 
Before 1989, none of the national epidemiological sur-
veys detected the presence of crack. However, lifetime use 
was 36% in 1993 and reached 46% in 19977 (A). About 2% 
of the Brazilian students have used cocaine at least once in 
their lifetime, and 0.2% used crack8 (A). Among the largest 
cities in the state of São Paulo, the lifetime use of cocaine 
reaches 2.1% of the population, becoming the third most 
widely used illicit substance after solvents (2.7%), and 
marijuana (6.6%), and the lifetime use of crack reaches 
0.4%9 (A). The use of crack is starting at ever-earlier ages, 
spreading across the country and across all social classes, 
with easy access and almost always preceded by alcohol 
and/or tobacco consumption10-12 (A)13,14 (B). 
The two national household surveys (2001 and 2005), 
conducted in 24 cities with over 200,000 inhabitants by 
the Brazilian Information Center on Psychotropic Drugs 
(Centro Brasileiro de Informações sobre Drogas Psico-
trópicas – CEBRID) showed that crack consumption has 
doubled, and the south region was the most affected, the 
lifetime use increasing from 0.5% to 1.1%, followed by the 
southeast region with 0.8%. In the north region, the high-
est lifetime use of merla (1.0%), another form of smoked 
cocaine, was found11 (A). The combination of crack use 
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with other behaviors was instrumental in the development 
of complications, such as the association with HIV infec-
tion, violence, and crime15,16 (B). 
Specialized outpatient services for addiction treatment 
began to experience the impact of consumption growth 
from the early 1990s, when the proportion of crack us-
ers in some centers increased from 17% (1990) to 64% 
(1994)17 (B). In emergency rooms, cocaine is responsible 
for 30% to 40% of admissions related to illicit drugs, 10% of 
hospital admissions among all kinds of drugs, and 0.5% 
of total admissions18 (B). Cocaine consumption compli-
cations requiring medical attention are usually acute and 
individual19 (B). Cocaine and crack users have great di -
culty in seeking specialized treatment because they do not 
recognize the problem, are faced with prejudice due to the 
illegality of the drug and its relation with crime, and nd 
that access to treatment is di cult and that specialized ser-
vices do not offer interventions tailored to their needs.
Because there is an increase of cocaine seizures in Bra-
zil, as well as in the number of users, an increase in us-
ers seeking treatment is also expected. Given the barriers 
encountered, such as access to treatment, current thera-
peutic model, and lack of team training prior to the new 
wave of patients and their complications, the purpose of 
this guideline may reduce the distance between the users’ 
needs and the currently available resources.
1. WHAT IS THE INCIDENCE AND PREVALENCE OF CRACK 
ADDICTION?
The use of crack is a recent phenomenon that emerged 
around 25 years ago in the United States20 (B) and 20 years 
ago in Brazil21 (C). In some European countries, this issue 
has become relevant just over Thve years ago22 (D). 
Qualitative studies of crack users began to be pub-
lished in the early 1990s in Brazil21 (C). Follow-up stud-
ies of addicts have only been completed and released from 
the second half of the 2000s onward23,24(B).
CEBRID conducted two national surveys on drug use 
in Brazil in 2001 and 2005 and found that the lifetime use 
of crack increased from 0.4% to 0.7% during this period. 
The largest increase occurred in the south (0.5% to 1.1%) 
and in the southeast (0.4% to 0.8%). In the northeast, 
there was an increased perception among respondents 
about the ease to obtain crack (19.9% in 2001 and 30.5% 
in 2005)25(B).
In the Thve surveys among students, and in the survey 
among street children and adolescents also conducted 
by CEBRID between 1987 and 2004, a trend towards in-
creased consumption was also found10,11 (A). Among street 
children, the Thrst increase occurred in São Paulo and Porto 
Alegre in the Thrst half of the 1990s, and in Rio de Janeiro, 
in the second half of the decade. Crack and cocaine arrived 
in the northeast region only in 200010 (A).
Most crack users (62.8%) present positive criteria for 
addiction during their drug-use careers26 (A). The inter-
val between the onset of consumption and occurrence of 
related problems was shorter for crack users (3.4 years) 
than for intranasal cocaine users (5.3 years)27 (C). When 
compared to intranasal cocaine users, crack users are more 
exposed to the risk of dependency because they use the 
drug more frequently, in larger quantities, and are more 
sensitive to the effects of the substance28 (B). Novice crack 
users seem to have twice the risk of dependency than users 
of inhaled cocaine, regardless of gender, ethnicity, associa-
tion with alcohol, or time of drug use29 (B). The risk of de-
pendence is more “explosive” with cocaine use, compared 
to marijuana and alcohol30 (B). 
According to the United Nations (UN), the demand 
for cocaine has declined in traditional markets, such as the 
United States, and gained ground in others, especially in 
Europe and developing countries like Brazil6 (D).
There was a signiThcant increase (7.4% to 42.6%) of 
crack users in Canada over ten years, with injectable co-
caine and crystal methamphetamine use, living in a city, 
and involvement with the sex trade as independent predis-
posing risk factors31 (B).
The Brazilian National Confederation of Municipali-
ties interviewed the health secretaries of all Brazilian mu-
nicipalities, and observed that 98% of the municipalities 
surveyed had problems related to crack, even those with 
less than 20,000 inhabitants32 (B).
RECOMMENDATION
Crack users are exposed to a greater risk of addiction28 (B), 
with twice the risk of dependence than inhaled cocaine us-
ers29 (B), and even greater risk when there is an association 
with cocaine, marijuana, and alcohol30 (B). The prevalence 
of crack use in Canada is 42.6%31(B), there is still no na-
tional data. There was an increase in crack consumption in 
Brazil, with the largest increase in the south region25 (B); 
however, 98% of the municipalities surveyed (most with 
more than 20,000 inhabitants) reported problems related 
to crack32 (B).
2. WHAT ARE THE RISK FACTORS FOR CONSUMPTION  
INITIATION AND DEVELOPMENT OF CRACK ADDICTION?
Risk factors are conditions or behaviors that increase the 
likelihood of negative outcomes for health, welfare, and 
social performance. Protective factors are those that pro-
mote healthy growth and prevent the risk of dependency 
and worsening of social problems33(D).
A follow-up study of injectable drug users found that 
almost half of the participants had already been consum-
ing crack for nine years, and that the previous use of in-
travenous cocaine, greater availability of drugs, and trad-
ing sex for drugs were directly related to increased risk of 
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starting its use31(B). Another study of street youth with HIV 
and/or hepatitis C found that the multiuse of substances 
increased the risk of starting crack use. The incidence rate 
for crack use in patients without previous use of cocaine 
was 136/1000 person-years (95% CI; 104-175), increasing 
to 205/1000 person-years (95% CI; 150-275) for those who 
have used cocaine34(B). However, studies that include us-
ers of various substances appear to corroborate the multi-
causal model of dependence as resulting from the interac-
tion of protective and risk factors33,35(D) – Box 1.
Family is one of the main agents capable of inuencing 
the individual vulnerability to initiate and establish prob-
lematic patterns of consumption, both directly by genetic 
transmission or exposure to consumption within the fam-
ily environment; and indirectly through violence, abuse, 
and continued stress, often due to rigid or chaotic family 
structures, poor communication among family members, 
and attachment relationships marked by insecurity and/or 
abandonment36-38(B). On the other hand, positive relation-
ships within the family are always protective and structur-
ing, reducing the vulnerability of individuals to drug use, 
and tending to prevent consumption from becoming an 
addiction36,39(B). Therefore, family and other parts of sub-
stance abusers’ lives should be continuously investigated 
for strengths and vulnerabilities in order to better plan and 
succeed in preventive and therapeutic actions40 (D).
An increasing prevalence of early crack consumption 
is observed, especially in situations of parties attended 
by young people, marginalized social groups, homeless, 
prostitutes, and patients dependent on opiates and/or co-
caine41 (B).
RECOMMENDATION
Both risk and protective factors for early consumption 
of crack must be known. Risk factors are: a) individual, 
such as the use of various substances (alcohol, cigarettes, 
cocaine, opiates31,34 (B)), and being part of a marginalized 
group41 (B); b) family and friends37,38 (B); c) environmen-
tal, such as community and school35 (D). Protective factors 
are those that reduce the vulnerability of individuals and 
may prevent addiction36,39 (B).
3. WHAT ARE THE SIGNS AND SYMPTOMS FOUND IN CASES 
OF CRACK ACUTE INTOXICATION/ABUSE AND HOW SHOULD 
THEY BE MANAGED?
Crack consumption is often associated with severe pat-
terns of dependence, varying along a continuum of sever-
ity42 (B). Studies have demonstrated occasional users43(B).
The acute complications related to cocaine use requir-
ing medical attention are individual44 (D). Psychiatric 
complications are frequent, occuring in 35.8% of cases20 
(B), particularly panic attacks, depression, and psycho-
sis45 (B) 46(C). Psychotic symptoms (paranoid delusions, 
hallucinations) can spontaneously disappear after a few 
hours (end of cocaine action), but extreme agitation may 
require intramuscular sedation with benzodiazepines 
(midazolam 15 mg). Haloperidol 5 mg may be used for this 
condition, but phenothiazine neuroleptics, such as chlor-
promazine and levomepromazine, should be avoided due 
to the signiffcant reduction in seizure threshold.
If an individual has a mental disorder associated with 
the use of drugs of abuse, the picture is more severe and in-
creases the likelihood of seeking treatment. Even when psy-
chiatric symptoms emerge, there is always the possibility of 
relation to clinical abnormalities, such as hypoglycemia and 
metabolic disorders, and confusional states triggered by in-
fections20 (B). Clinical complications and mental disorders 
are the most common presentations (57.5%), followed by 
cardiopulmonary complications (56.2%). Regarding neu-
rological complications, 39.1% of the most common symp-
toms are seizures, focal neurological symptoms, headaches, 
and transient loss of consciousness20 (B). Therefore, the 
psychiatric diagnosis in a medical emergency should be 
syndromic or symptomatic, as the approach is focused on 
the psychiatric symptoms and there is a shortage of time 
and incomplete patient history18 (B).
There is no consensus on the dose of cocaine, much 
less that of crack, needed to trigger serious health prob-
lems or even threaten the user’s life, but it is believed that 
consumption of about 2 to 4 mg/kg produces a slight re-
duction of coronary blood ffow and an increase of equal 
magnitude in heart rate and blood pressure47 (D). In addi-
tion to the inherent toxicity of the substance, the presence 
of concomitant diseases in the organs most affected by the 
sympathomimetic action of cocaine makes these patients 
even more susceptible to complications, such as coronary 
artery disease, arterial hypertension, aneurysms, epilepsy, 
and chronic obstructive pulmonary disease48 (D).
Among the acute complications associated with co-
caine use, overdose is the most known and is considered a 
medical emergency. It can be deffned as the failure of one 
or more organs caused by acute substance use and conse-
quent increase in central and sympathetic stimulation49(C). 
The clinical signs of cocaine overdose are: palpitations, 
sweating, headache, tremor, anxiety, hyperventilation, 
muscular spasm; and signs of adrenergic overstimulation, 
such as mydriasis, tachycardia, hypertension, arrhythmia, 
and hyperthermia. It can progress to seizures, angina pec-
toris with or without infarction, intracranial hemorrhage, 
and rhabdomyolysis, leading to death, often due to heart 
failure and/or respiratory failure.
Cardiovascular complications resulting from cocaine 
consumption are the most common among non-psychi-
atric disorders, with angina pectoris reaching the highest 
rate, present in 10% of users50-52 (A). Acute myocardial in-
farction (AMI) is not so frequent39 (A). About one-third of 
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Box 1
strokes in young adults are associated with drug use, and, 
among adults aged 20-30 years, this rate reaches 90%53 (A). 
Seizures, the most common neurological complication, af-
fect a small proportion of cocaine users who seek emer-
gency rooms54 (B).
Regarding pulmonary complications caused by acute 
use of crack, the most common symptoms, developing 
within hours after use, are: chest pain, dyspnea, dry cough 
or elimination of blood and/or dark material (combus-
tion waste), and fever55 (D). Thermal injury, inhalation 
Risk and protective factors in different aspects of life35 (D)
Risk factors Protective factors
Individual Individual
*Genetic predisposition *Beliefs, moral and religious values
*Low self-esteem, feelings of hopelessness about life *Positive orientation towards health and perception of risks of 
drug use
*Perceived approval of drug use by friends *Perception of social sanctions and controls,  intolerance to 
deviant behavior, and good relationships with adults
*Problems with social bonding; rebellious, deﬁant, and 
resistant to authority personality
*Competent and assertive social skills, such as empathy, 
pragmatism, and good self-control
*Sensation-seeking behavior pattern, curiosity, impulse control 
problems
*Deﬁcits in skills for coping with situations
Friends Friends
*Psychoactive substance users and/or those with deviant 
behavior
*Followers of conventional models of behavior and social 
norms
* Favorable attitudes towards drug use *Intolerant to deviant behavior
Family Family
*Chaotic and conﬂictive home environment *Supportive, harmonic, stable, and safe family environment, 
with clear rules of conduct and parental involvement in their 
children’s lives
*Low bonding, poor relationship among members *Strong, safe, and stable family bonding and relationships
*Consumption or attitudes that favor substance use by parents 
or other members
*Stronger norms and moral values
*Inconsistent and low supportive parenting, lack of monitoring
*High and unrealistic expectations by family members
School School
*Academic failure *Social integration among students policies, and school 
performance monitoring
*Poor school involvement and adjustment * School norms that discourage violence and psychoactive 
substance use
* Peer rejection, bullying * Positive school climate, targeted towards bonding
*Unrealistic expectations and lack of institutional support 
Community Community
*Availability of substances, consumption encouragement, and 
lack of legislation and law enforcement for illicit drugs
*Access to health and social welfare services
*Violence, poverty, and lack of social support * Safety, organization, and community norms against violence 
and drug use
*Social disorganization and absence of the State *Leisure activities, community ties, and religious practices
*Cultural identity and ethnic pride
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of impurities, local anesthetic effect, and vasoconstric-
tion causing inThammation and necrosis are primarily re-
sponsible for airway lesions55 (D). Hemoptysis occurs in 
6% to 26% of users. Pleural effusion may also be present55 
(D). There are still few studies that directly relate the risk 
of tuberculosis and other infections in crack and cocaine 
users56 (C).
DetoxiThcation is a short-term approach (two to four 
weeks) performed either in an outpatient/home or hospi-
tal setting57 (D). This approach is being increasingly valued 
in the treatment process of users, as it seems to increase 
adherence to subsequent treatments58,59 (B).
RECOMMENDATION
Crack users who seek medical care immediately after con-
suming crack frequently present with psychiatric symp-
toms44 (D).
However, changes related to clinical symptoms, such 
as hypoglycemia, metabolic disorders, and confusional 
states triggered by infections, should always be investi-
gated20 (B). Overdose is the best known clinical compli-
cation, although unusual49 (C). Crack users need speciThc 
pulmonary assessments55 (D). Referral to short detoxiThca-
tion treatment may increase the adhesion to subsequent 
treatments58,59 (B).
4. WHAT ARE THE SIGNS AND SYMPTOMS OF CRACK  
DEPENDENCE AND ABSTINENCE SYNDROME AND HOW TO 
START TREATMENT?
Dependence on alcohol, tobacco, and other drugs – in-
cluding crack – is considered a syndrome characterized by 
the presence of a compulsive use pattern, generally aiming 
towards the relief or avoidance of withdrawal symptoms; 
this pattern is more important than part or all of the social 
commitments and activities undertaken by the individual, 
who starts to neglect or abandon them in order to favor 
the use. This pattern usually results in tolerance and absti-
nence syndrome60 (D).
During abstinence, periods of intense craving for co-
caine, together with other withdrawal symptoms, includ-
ing fatigue, anhedonia, and depression, eventually lead 
back to drug use61 (C). In chronic users, abstinence syn-
drome is well observed, but it can appear even in those 
who used the drug for a few days, in a compulsive or binge 
use form61 (C). The syndrome is composed of three phas-
es: crash, late dysphoric syndrome, and extinction. These 
phases represent the progression of signs and symptoms 
after the cessation of use and are described below61 (C):
t Phase I – Crash: a drastic reduction in mood and 
energy that happens about 15 to 30 minutes after 
the use of the drug, which persists for about eight 
hours and may extend for up to four days. The user 
may experience depression, anxiety, paranoia, and 
an intense desire (craving) to return to drug use. 
Hypersomnia and aversion to the substance then 
occurs, and the person wakes up on a few occasions 
to eat in large quantities. This last step can last from 
eight hours to four days; 
t Phase II – Late dysphoric syndrome: begins 12 to 
96 hours after the substance use and may last from 
two to 12 weeks. In the Thrst four days, there is the 
presence of sleepiness, craving for the drug, anhe-
donia, irritability, memory problems, and suicidal 
ideation. Relapses occur frequently as a way of re-
lieving dysphoric symptoms;
t Phase III – Extinction: in this phase the dysphoric 
symptoms diminish or completely cease, and cra-
ving becomes intermittent.
Although cocaine withdrawal symptoms are less in-
tense and appear to decrease linearly in hospital settings, 
in outpatient treatment they are more frequent, intense, 
and last longer62 (B). Trigger factors and conditioned stim-
uli have a great inThuence and represent a real potential for 
relapse in users63 (B).
Psychiatric complications are the main reason for 
seeking medical attention among cocaine users45 (B). 
They may result from acute intoxication and substance 
withdrawal64,65 (B). They worsen the prognosis and, if not 
detected, new relapses and treatment discontinuation can 
occur66 (B).
In addition to using a broad pharmacological arsenal 
for the stabilization of psychiatric and medical conditions 
resulting from neural and sympathomimetic deregula-
tion, it is necessary to manage the withdrawal symp-
toms67,68 (D). DisulThram, still under study, has been used 
to alleviate drug craving and urgency69 (A) 70(B), as well as 
modaThnil71,72 (A). Topiramate is recommended to reduce 
the drug-seeking behavior73,74 (A) 75(B). Cocaine vaccines 
are being developed to reduce relapse, but are still far from 
being marketed76 (A).
TOPIRAMATE
Topiramate’s mechanism of action enhances the tone of 
the GABA neurotransmission system and inhibits the 
AMPA/kainate glutamate receptor system. This increase 
in inhibitory activity (GABA) and blockade of excitatory 
activity (glutamate) cause a reduction in dopamine re-
lease in the nucleus accumbens, part of the reward system. 
Thus, the pharmacological proThle of topiramate, at least 
in theory, reduces the magnitude of cocaine’s effects and 
drug-seeking behavior67 (D). Although meta-analyzes do 
not report a statistically signiThcant positive response of 
this anticonvulsant in cocaine dependence treatment73,74 
(A), studies with small samples, but placebo-controlled, 
have found that topiramate has a positive action on co-
caine dependence75 (B).
GUIDELINES IN FOCUS
146 Rev Assoc Med Bras 2012; 58(2):141-153
It has been found that, for many patients, the effect oc-
curs at a dose of 200 mg, with best results at a dose of 300 
to 400 mg/day77 (D). The most frequently reported adverse 
effects are nervousness, abnormal thinking, impaired 
memory, nausea, weight loss, and language and concen-
tration/attention disorders78 (D).
DISULFIRAM
The pharmacological properties of disulram, which re-
sults in alcohol aversion, have been known since the 
1930s, and became formally recognized and approved as 
a medication for alcohol dependence since the 1950s. This 
well-known substance for treating alcohol dependence ap-
peared recently as the drug most supported by evidence for 
treating cocaine-dependent individuals69 (A). There was a 
trend in favor of disulram compared to control, but not 
statistically signicant in the assessment of reduced cocaine 
use, with RR = 0.82 (95% CI; 0.66-1.03). However, there is 
benet in maintaining three or more consecutive weeks of 
abstinence, with RR = 1.88 (95% CI; 1.09-3.23)69 (A).
In addition to inhibiting aldehyde dehydrogenase, a 
mechanism of aversive therapeutic action, which leaves 
the individual more attentive and organized, in order to 
prevent relapse and adverse effects of alcohol consump-
tion79 (B), disulram also acts on the dopamine system, in-
hibiting the conversion of dopamine into norepinephrine 
by blocking dopamine -hydroxilase (DBH) and mono-
amine oxidase-B enzymes77 (D).
The recommended daily dose of disulram is 250 to 
500 mg/day. The drug action and metabolism are well tol-
erated and relatively safe, but contraindicated for patients 
with serious liver diseases, such as hepatitis and decom-
pensated cirrhosis67 (D) 69(A). Patients should be well in-
formed about the risks and effects of disulram secondary 
to alcohol intake. In these circumstances, the increase in 
aldehyde circulation causes changes ranging from physi-
cal and psychological discomfort, such as facial and chest 
ushing, feeling of warmth, nausea, anxiety, and panic re-
actions, to even more severe complications, such as respi-
ratory depression, seizures, neurological disorders, cardiac 
arrhythmias, cardiogenic shock, and acute myocardial in-
farction, which may lead to death80 (C). Thus, before start-
ing treatment, it is recommended that a written informed 
consent is obtained from the patient with the approval of 
one of his relatives. Cognitive impairments or comorbidi-
ties that compromise the proper understanding of the risks 
involved and presence of suicidal or impulsive behaviors 
are, at the least, relative contraindications for this drug.
MODAFINIL
Modanil is a central nervous system stimulant. Simi-
lar to cocaine, but in a milder form, modanil blocks the 
reuptake of dopamine and noradrenaline, increasing its 
concentration in the brain81 (A). The molecule can also in-
crease the glutamate system activity, which is usually de-
cient due to the chronic use of cocaine. Such compensation 
could block the euphoric effects of cocaine and prevent the 
return of the drug-seeking behavior67 (D). The drug ap-
pears to be well tolerated. The adverse events most com-
monly observed (5%) are headache, nausea, nervousness, 
anxiety, insomnia, diarrhea, dyspepsia, and dizziness77 (D).
Open studies have found increased rates of treatment 
adherence and abstinence among patients treated with 
doses of 200 to 400 mg/day77 (D). Despite the promising 
initial ndings, meta-analyzes have not conrmed these 
results on the use of stimulants such as modanil and 
methylphenidate for treatment of cocaine users. They ap-
pear not to reduce cocaine use, despite the trend towards 
maintenance of abstinence, with RR = 1.41 (95% CI; 0.98-
2.02; p = 0.07); therefore, all results showed no signicant 
statistical difference82 (A). Thus, e cacy conrmation re-
lies on the results of further studies.
RECOMMENDATION
Cocaine withdrawal symptoms are mainly psychological, 
particularly depressive and anxiety symptoms61 (C). Gen-
erally, these symptoms become more intense in the ftrst 7 
days, decreasing in intensity afterwards. They appear to be 
less intense when the patient is in a protected enviroment62 
(B). Disulftram, at a dose of 250 to 500 mg/day presents 
beneftt in the treatment of cocaine-dependent individuals, 
increasing the possibility of maintaining abstinence69 (A). 
Modaftnil at a dose of 200 to 400 mg/day has no statistical-
ly signiftcant beneftts, despite the tendency to maintain ab-
stinence82 (A). Topiramate at a dose of 200 to 400 mg/day, 
so far, has not shown beneftts for treating cocaine-depen-
dent individuals73,74 (A).
5. HOW SHOULD THE INITIAL ASSESSMENT OF THE CRACK 
USER BE MADE?
Among illicit drug users, crack users are less likely to 
seek treatment83 (B) 84(C). They seek treatment in acute 
situations and prefer intervention approaches in hos-
pital settings, with low adherence in the later outpatient 
stage23,85,86 (B). For cocaine users, treatment-seeking takes 
place around the sixth and seventh year of use, but earlier 
among crack users87 (B).
The initial assessment is a very important moment 
that depends on the expertise of the professional or ser-
vice, but requires an intensive approach given the degree 
of disruption caused by the substance consumption88,89 
(B). Risk assessment should be prioritized in order to 
solve the critical problems, to promote the patient’s men-
tal balance through an active management, anticipating 
risk situations and resolving them promptly to avoid re-
suming consumption90 (D).
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Because crack consumption has been directly associ-
ated with HIV infection, HIV testing is essential91 (B).
RECOMMENDATION
Crack-dependent individuals require more intensive ap-
proaches due to the degree of disruption caused by sub-
stance consumption88,89 (B), in addition to having the low-
est rates of adherence to treatment compared to patients 
using other substances90 (D).
6. WHAT ARE THE PSYCHIATRIC COMORBIDITIES RELATED TO 
CRACK CONSUMPTION?
The prevalence of mental disorders is higher among crack 
users compared to users of inhaled cocaine and is corre-
lated with age (r = 0.124), days of cocaine use per month 
(r = 0.370), number of years of regular crack use (r = 0.109), 
and severity of cocaine dependence (r = 0.502), all sig-
niffcant92 (B). This ffnding is associated with the severity 
of dependence and with combined psychosocial factors93 
(B). When crack users have a primary mental disorder, the 
vulnerability is increased and associated comorbidity was 
present in 36.4% 26 (B) to 42.5% of cases94 (B).
Depression (26.6%) and anxiety (13%) are the most 
frequent psychiatric comorbidities, affecting almost half 
of the users94(B). Depressive symptoms secondary to 
consumption are the most prevalent94,95(B). The intensity 
of crack consumption appears to be directly related to 
the risk of developing depressive disorder in up to 64% 
of cases96 (B). Depression affected almost all crack users 
who consume alcohol and are infected with HIV,  totalling 
73.5% of cases97 (B). Increased risk of suicidal ideation or 
suicide attempt was observed among Brazilian users98 (B).
Crack users consume alcohol less frequently and less 
heavily than inhaled cocaine users14 (B). Alcohol con-
sumption is a predictor of severity and poor prognosis for 
the user of any substance, including crack99 (B). In a four-
year follow-up study, a greater chance of alcohol depen-
dence was found among crack and alcohol users (67.9%) 
than in heavy alcohol users (13.6%), with OR = 12.3 for 
men and OR = 7.0 for women100 (B). The presence of al-
cohol during cocaine consumption originates cocaethyl-
ene, an active metabolite responsible for a more intense 
and longer lasting action on the reward system, but it is 
more toxic than cocaine, which increases the risk of sud-
den death among users101 (B).
The multiuse of substances is common among crack 
users102 (D). Marijuana is used in order to reduce the 
anxiety and craving resulting from the use of crack103 (C). 
There is also a group of users who use both crack and in-
haled cocaine104 (A) 14(B).
Personality disorders are common among illicit drug 
users and affect most drug and alcohol users, a com-
mon situation among crack users105 (A) 94(B). Antisocial 
personality disorder and borderline personality disorders 
are the most common106 (A) 86(B). The greater the severity 
of the personality disorder, the worse the prognosis and 
more remote the chances of adherence to treatment107 (D). 
On the other hand, patients with avoidant and schizoid 
personality disorders appear to have a less severe con-
sumption and to be more likely to seek treatment108 (B).
Schizophreniform symptoms, in most cases transient, 
are often observed in users of both crack and inhaled co-
caine106 (A).
RECOMMENDATION 
The use of crack is often associated with psychiatric co-
morbidities105,106 (A) 94,96 (B), and when users present with a 
primary mental disorder, the association is even higher26,94 
(B). Multiuse of substances is common103 (D). Although 
crack users usually consume less alcohol than inhaled co-
caine users86 (B), alcohol consumption predicts severity 
and poor prognosis99 (B).
7. DO URINE TESTS, HAIR ANALYSIS, AND NEUROIMAGING 
TECHNIQUES HELP IN THE DIAGNOSIS OF PROBLEMATIC USE 
AND DEPENDENCE ON CRACK? 
Analysis of psychotropic substances in body ffuids (urine, 
blood, saliva) and hair has two main purposes: (1) emer-
gency diagnosis; (2) clinical management and monitoring 
of chronic use during treatment109 (C). In addition to con-
ffrming the good evolution of the proposed treatment, re-
peated negative urine samples can be a motivation for the 
patient being treated110 (B).
There are ethical precepts for drug testing in patients:
t The use of a test to prove abstinence to third par-
ties (judges, employers, family members) or even 
to provide security to the group that interacts with 
the user is not justiffed;
t The problematic user has great diff culty to self- 
determine abstinence, no matter how much he/she 
wants it, and to gain autonomy, because the addic-
tion dominates his/hers behavior;
t The temporary use of compulsory methods of con-
trolling and monitoring (testing and use of aversive 
drugs) aims to eliminate the addictive behavior in 
order to rectify, restore, and enhance the capacity 
for autonomy. It would be “mandating treatment in 
the name of autonomy”111 (D).
Urine drug testing is indicated to detect the recent use 
of cocaine and crack, with the presence of the substance 
and its metabolites (even in the case of coca tea), for up to 
ffve days after the last intake112,113 (D). It uses anti-benzoy-
lecgonine (BZE) antibody, one of the major metabolites of 
cocaine114 (A), considered as true-positive when the pres-
ence of BZE is at or above 40%115 (A). It is indicated for 
high-risk situation management, which requires constant 
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Box 2
Neurological changes resulting from acute and chronic use of cocaine
1. The acute use of cocaine decreases the mean consumption of glucose by the brain, causes acute decrease in blood ﬂow 
to regions such as the prefrontal cortex and basal ganglia — all involved in behavior reinforcement of dependency.
2. The intensity of the euphoric effects of cocaine is directly proportional to the blockade of dopamine reuptake by the 
substance. This blocking is more intense if the chosen route of administration is the lung (crack), followed by intravenous 
and intranasal, which partly explains the crack’s ability to generate more dependency. From this observation, drugs that 
occupy the dopamine transporter proteins, such as modaﬁnil, have been studied in order to reduce the craving and positive 
effects of cocaine.
3. Among chronic users, the mean reduction of glucose consumption by neurons and blood hypoperfusion may last for 
weeks, months, or indeﬁnitely. Reduction of dopaminergic receptors, particularly type 2 (D2) is also observed. There is 
reduced white matter integrity in the frontal cortex region, a change related to increased impulsivity in users.
4. Neuroimaging has contributed to the understanding of craving124-126 (C).
monitoring for short periods, as constant testing tends to 
lose effectiveness and trouble the patient when too pro-
longed113 (D).When BZE measurement is performed by 
gas chromatography-mass spectrometry, there is a sensi-
tivity of 97.6%, and specicity of 60.5%, with a positive 
predictive value of 71% and negative predictive value of 
97%. Considering the pretest probability (prevalence) of 
42%, and likelihood ratio of 2.5 (95% CI; 1.95-3.20) when 
BZE measurement is positive, there is an increase in post-
test probability (or denite diagnosis) by 64%116 (B).
Hair analysis is a method to investigate the previ-
ous use of cocaine and to monitor sustained abstinence, 
which detects drug consumption with more sensitivity 
during the preceding 120 days, with the exception of the 
last 30 days117 (C) 113(D). It is specic for cocaine and co-
caethylene, as its major metabolite, benzoylecgonine, can 
generate false-positive results and, therefore, it is not part 
of the method118 (D). Hair analysis may be performed by 
two methods: radioimmunoassay and gas chromatog-
raphy-mass spectrometry117 (C). The Thrst method has a 
sensitivity of 67.8% and speciThcity of 80.5%. Consider-
ing the same pretest probability (prevalence) of 42%, and 
likelihood ratio of 3.54 (95% CI; 2.31-15.42), positive 
hair analysis by radioimmunoassay increases the diag-
nostic certainty to 72%. The second method has a sensi-
tivity of 75%, speciThcity of 97.4%, and likelihood ratio of 
37.13 (95% CI; 9.27-147.06); therefore, the spectrometric 
hair analysis increases the likelihood of disease from 42% 
to 96%119 (B).
Caution should be exercised in interpreting hair anal-
ysis: (1) cocaine metabolites can be detected up to three 
months after withdrawal versus consecutive negative tests 
for cocaine in urine up to 90 days; (2) the hair does not 
grow uniformly throughout the scalp, which can give the 
false impression of consumption in last month; (3) there 
is the possibility of external contamination of hair by 
contact with the sweat of others or reduced substance or 
the use of products for hair care, extremely remote pos-
sibilities. There is no statistically signiThcant difference 
between male and female hair analysis. The median half-
life of cocaine in hair is 1.5 months (95% CI; 1.1-1.8) for 
men and 1.5 months (95% CI; 1.2-1.8) for women120 (B).
The neuroimaging test used to detect addiction con-
sists of a set of non-invasive techniques used in studies of 
brain dysfunction secondary to drug use. The main Thnd-
ings related to cocaine use are shown in Box 2. Neuroim-
aging techniques have helped researchers to detect brain 
changes caused by other disorders that increase the vul-
nerability or potencialize the use of drugs of abuse121(D). 
Despite the current and potential advances, neuroimag-
ing does not have clinical indications for diagnosis and 
treatment of addiction122,123 (D).
RECOMMENDATION
Screening for cocaine and its metabolites in body Thuids 
helps in the diagnosis of psychotropic substance acute in-
toxication and allows conThrmation of abstinence  during 
treatment110 (B).
Diagnosis of previous cocaine consumption up to 120 
days, except for the last 30 days and/or prolonged with-
drawal monitoring, can be done through hair analysis 
by radioimmunoassay119(B) and by gas chromatography-
mass spectrometry117(C). To detect the use of cocaine and 
crack within the previous Thve days, the measurement of 
cocaine metabolites (BZE) in urine is performed116 (B). 
Despite the current and potential advances, neuroimaging 
does not have clinical indications for diagnosis and treat-
ment of addiction122,123 (D).
8. WHAT ARE THE EFFECTS OF CRACK USE ON PREGNANCY 
AND ON THE NEWBORN?
Certain phenomena associated with cocaine use during 
pregnancy, such as the substance effects on pregnancy de-
velopment for both mother (placenta, infections etc.) and 
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fetus, as well as the presence of withdrawal syndrome after 
birth have called the attention of researchers and health 
professionals.
It is known that cocaine increases the replication of 
HIV in vitro and that cells of chronic cocaine users favor 
viral replication and entry of opportunistic infections, 
when compared to non-users. Perinatal transmission can 
occur by three mechanisms:
1. Before birth, by transplacental infection.
2. During labor, by contact with the mother’s Thuids.
3. After birth, through breastfeeding.
Cocaine appears to increase the risk of HIV transmis-
sion at least by the Thrst two mechanisms, as it increases 
viral replication and affects fetal immune development127 
(D). Infants born to crack users are more exposed to infec-
tions (OR = 3.09; 95% CI; 1.76-5.45), including hepatitis 
(OR = 13.46; 95% CI; 7.46-24.29), acquired immunodeTh-
ciency syndrome (OR = 12.37; 95% CI; 2.20- 69.51), and 
syphilis (OR = 8.84; 95% CI; 3.74-20.88)128 (B).
Results regarding the impact of fetal exposure to co-
caine are still inconsistent129 (D). There is no evidence of a 
teratogenic syndrome130 (D). Crack use during pregnancy 
appears not to lead, invariably, to the birth of infants with 
severe, persistent, and unusual damages—the “crack ba-
bies”131 (D).
The strongest evidence of damage related to cocaine 
use during pregnancy is the risk of premature birth and 
low birth weight128,132 (B). A follow-up study of crack us-
ers divided into two groups (with and without prenatal 
care) found intrauterine growth retardation and low 
birth weight in relation to the populational mean, regard-
less of the presence of pre-natal care133 (B). Regarding 
infants born to crack users, there were 19% premature 
births, lower weight (536 grams), lower height (2.6 cm), 
and smaller head circumference (1.5 cm)134 (B). Changes 
in the central nervous system are frequently seen, such 
as permanent alertness (OR = 7.78; 95% CI; 1.72-35.06), 
excessive sucking (OR = 3.58; 95% CI; 1.63-7.88), and au-
tonomic instability such as tachycardia, sweating, labile 
pressure, hyperthermia (OR = 2.64; 95% CI; 1.17-5.95), 
frequent crying (OR = 2.44; 95% CI ;1.06-5.66), nervous-
ness and/or tremor (OR = 2.17; 95% CI; 1.44-3.29), and 
irritability (OR = 1.81; 95% CI; 1.18-2.80)128 (B).
A study of neurological disorders in infants born to 
crack users found a relationship between intensity of co-
caine use and presence of neurological disorders, such as 
abnormalities in muscle tone and posture135 (B), in addi-
tion to signiThcant changes in behavior up to Thve years of 
age136 (B).
Few studies have found differences between children 
of mothers who use crack and of non-users, both re-
garding complications at birth137 (B) and development138 
(C). There is no convincing relationship between the use 
of cocaine/crack during the prenatal period and toxic 
changes in child development, noting that the social, en-
vironmental, and psychosocial variables of the pregnant 
women (multiuse of drugs, education, maternal nutri-
tional status etc.) play a decisive role in the occurrence 
of the behavioral and physical damage observed139,140 
(A) 141,142(B).The socioenvironmental and psychosocial 
characteristics of the mother also appear to inThuence the 
pregnancy and fetus, along with cocaine consumption143 
(B). Children born to crack users are less breast-fed 
(OR = 0.26; 95% CI; 0.15-0.44), use more child protec-
tion services (OR = 48.92; 95% CI; 28.77-83.20), and of-
ten are not raised by the biological mother (OR = 18.70; 
95% CI; 10.53-33.20)128 (B).
Neonatal cocaine withdrawal syndrome is character-
ized by irritability, hypertonicity, tremors, mood swings, 
and continuous crying144 (C). Withdrawal symptoms do 
not appear to be as common among children of cocaine 
users145 (B). A study of pregnant crack/cocaine users 
performed urinalysis in all newborns and found the fol-
lowing: (1) infants whose mothers did not use cocaine 
for seven days or more probably showed symptoms of 
withdrawal in utero, without repercussion after delivery; 
(2) those positive for the substance for a day or less did 
not show withdrawal symptoms; (3) neonates positive for 
cocaine between the second and sixth day of birth had a 
higher incidence of neonatal withdrawal symptoms and 
were conditioned to the cocaine use by the mothers dur-
ing the immediate period after childbirth146 (C).
RECOMMENDATION
The use of crack during pregnancy leads to intrauterine 
growth retardation and low birth weight128 (B), increases 
the risk of premature birth134 (B), and exposes children 
to infections such as hepatitis, human immunodeThciency 
virus, and syphilis128 (B).
Neonatal cocaine withdrawal syndrome is related to 
cocaine use by mothers during the immediate period af-
ter childbirth146 (C), is infrequent145, (B) and is character-
ized by irritability, hypertonicity, tremors, mood swings, 
and continuous crying144 (C).
Children born to crack users are always alert, present 
with excessive sucking, autonomic instability, frequent 
crying, tremors, and irritability128 (B). They also have 
muscle tone and postural abnormalities135 (B) and behav-
ioral changes up to the preschool period136 (B).
9. DO CHILDREN OF CRACK USERS PRESENT WITH  
IMPAIRED NEUROLOGICAL AND COGNITIVE DEVELOPMENT?
The available evidence on the relationship between the 
exposure to cocaine/crack during pregnancy and pres-
ence of neurodevelopmental damage is still inconsistent 
and controversial.
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From birth to age seven, the children of cocaine users 
present higher incidence of low birth weight and are twice 
as likely to be below the average height for their age147 (B). 
Children aged 10 who were exposed to crack consump-
tion in the Thrst trimester of pregnancy have slower growth 
throughout childhood compared to controls of similar age 
not exposed to the drug, suggesting that intrauterine ex-
posure to cocaine has a long lasting effect148 (B). However, 
some studies found no relationship between cocaine use 
and development changes139,140 (A).
There seems to be some relationship between cocaine 
use during pregnancy and damage to cognitive and be-
havioral functioning149(A) 136,150(B), with a probability 
of cognitive impairment (OR = 1.98; 95% CI; 1.21-3.24; 
p = 0.006), without motor abnormalities. The potential 
reversibility of such changes is still unclear132 (B). Ex-
posed children have lower language skills than those not 
exposed – a signiThcant difference that remained stable 
over the Thrst three years of life151 (A). A similar study 
found no relationship152 (A); thus there is still contro-
versy on this subject.
The interaction between intrauterine exposure to co-
caine and quality of the mother’s environment was as-
sessed in a four-year follow-up study of infants exposed 
and not exposed to the substance during pregnancy. No 
difference was found in the indexes of general intelligence 
and cognitive performance between groups, but the ex-
posed group had more speciThc cognitive impairments 
(verbal performance, attention, IQ test/arithmetic, and 
acquisition of new knowledge)153 (A). Nevertheless, the 
inThuence of environmental factors may never be disre-
garded, as the same study compared the exposed children 
sent to well-structured foster homes with those raised by 
their biological parents (users and nonusers), Thnding a 
better school performance among the Thrst.
RECOMMENDATION
Children of crack users have a reduced weight and height 
development147 (B), but there is still controversy on the 
damage to psychomotor and cognitive development, as 
there are studies that found no relationship139,140,152 (A), 
while others found cognitive and behavioral impair-
ments, but not motor149 (A).
10. IS THERE EVIDENCE THAT GENETIC FACTORS HAVE A 
ROLE IN CRACK ABUSE AND ADDICTION?
Several genetic associations related to cocaine depen-
dence are being studied — a highly prevalent disorder 
involving multiple genes154 (B). Because a part of cocaine 
addicts consists of multi-drug users, multiple genes have 
been studied. Regions of human chromosomes 4, 5, 9 to 
11, and 17 are more likely to have genes susceptible to 
substances, and there is moderate to high heritability for 
most vices155 (B). The heritability rate of addictive use of 
stimulants, sedatives, and heroin for men is 0.33, 0.27, 
and 0.54, respectively156 (B).
It is also known that the earlier the exposure to co-
caine in animals, the greater the impairment of matu-
ration and the onset of mental and behavioral disor-
ders157-159 (D). In these animal models, there is evidence 
of the different chromosomal combinations of alleles and 
also of the alleles related to cocaine use160,161 (D).
Based on genetic studies of cocaine users, pharma-
cogenetic studies have proposed some substances for the 
treatment of cocaine addiction, such as disulram and 
methylphenidate162 (D).
By studying siblings of cocaine abusers, it was found 
that probands have proportional risk for cocaine addic-
tion (HR = 1.71; 95% CI; 1.29-2.27)163 (B).
RECOMMENDATION 
There is evidence of familial transmission of cocaine 
dependence154,163(B) and high to moderate heritability for 
most addictions156 (B). The knowledge that genetic fac-
tors contribute to abuse and facilitate the development 
of crack dependence is being used in pharmacogenetic 
research in order to provide specic treatments for co-
caine-dependent individuals162 (D).
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